Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 6/20 | 0.42 |
| ▸ | NT5E | P21589 | 2/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.38 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.38 |
| ▸ | HINT1 | P49773 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21489259 | 0.92 | IMPDH2 (0.42) | STING1NT5EIMPDH2IMPDH1HINT1 | |
| SCHEMBL21473300 | 0.91 | STING1 (0.45) | STING1NT5EIMPDH2IMPDH1HINT1 | |
| SCHEMBL21489355 | 0.91 | STING1 (0.45) | STING1NT5EIMPDH2IMPDH1HINT1 | |
| SCHEMBL21489171 | 0.91 | STING1 (0.47) | STING1NT5EHINT1HPGDFUT5 | |
| SCHEMBL21489178 | 0.88 | STING1 (0.38) | STING1NT5EIMPDH2IMPDH1HINT1 | |
| SCHEMBL21489368 | 0.84 | HINT1 (0.51) | STING1NT5EHINT1FUT5 | |
| SCHEMBL21504648 | 0.83 | IMPDH2 (0.42) | STING1NT5EIMPDH2IMPDH1HINT1 | |
| SCHEMBL21489257 | 0.83 | IMPDH2 (0.42) | STING1NT5EIMPDH2IMPDH1HINT1 | |
| SCHEMBL21489244 | 0.83 | POLB (0.39) | IMPDH2IMPDH1TAS1R3TAS1R1 | |
| SCHEMBL21489419 | 0.83 | IMPDH2 (0.42) | NT5EIMPDH2IMPDH1HINT1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242569-A1 | PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE | 2023-08-03 | — | — | US | disclosed |
| US-11613554-B2 | Phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-03-28 | — | — | US | disclosed |
| US-20190322694-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242569-A1 | PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | PPIP5K2, INPP5B, PTMS | STING1 4287/4885NT5E 472/4885IMPDH2 1266/4885 |
| US-11613554-B2 | Phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compounds | PPIP5K2, INPP5B, PTMS | STING1 4287/4885NT5E 472/4885IMPDH2 1266/4885 |
| US-20190322694-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | PPIP5K2, INPP5B, PTMS | STING1 4067/4885NT5E 379/4885IMPDH2 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.